Error loading player: No playable sources found

Player size: small large

JL1106ES

JL1106ES: Comparative Real-world (RW) Evidence on Darolutamide (Daro), Enzalutamide (Enza), and Apalutamide (Apa) for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) Patients (Pts) in the United States (DEAR)

Date

October 30, 2023

Explore related products in the following collection:

JADPRO 2023 Posters

Full author listing

Alicia K. Morgans, MD1 Neal D. Shore, MD2 Nasreen Khan, PhD3 Niculae Constantinovici, MD4 Javeed Khan, MSc5 Guifang Chen, MSc3 Julie Xu, MSc6 Jorge Ortiz, MD3 Daniel J. George, MD7

1Dana-Farber Cancer Institute, Boston, MA, USA; 2Carolina Urologic Research Center, Myrtle Beach, SC, USA; 3Bayer HealthCare, Whippany, NJ, USA; 4Bayer Consumer Care AG, Basel, Switzerland; 5Bayer plc, Reading, United Kingdom; 6Bayer Canada, Mississauga, ON, Canada; 7Duke University Cancer Institute, Durham, NC, USA

Presenter

Pam Ostby, PhD, RN, OCN

Senior Medical Science Liaison, Bayer US Pharmaceuticals

Tracks

Encore Poster - Solid Tumor

Related Products

Thumbnail for JL1129ES: Symptoms and Impacts Important to Patients With Advanced/Metastatic Non-small Cell Lung Cancer (Adv/Met NSCLC): Results of a Qualitative Research Study

JL1129ES: Symptoms and Impacts Important to Patients With Advanced/Metastatic Non-small Cell Lung Cancer (Adv/Met NSCLC): Results of a Qualitative Research Study

Full author listing Authors: Cardellino, A, MPH1; Shah, M, MPH1; Hanlon, J, MPH2*; Taiyari, S, MSc3; Kelly, K, PhD4; Roborel de Climens, A, PhD5; Stojadinovic, A, MD1*

Thumbnail for JL1130ES: Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study

JL1130ES: Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study

Arun A. Azad, MBBS, PhD, FRACP,1 Karim Fizazi, MD, PhD,2 Nobuaki Matsubara, MD,3 Fred Saad, MD,4 Ugo De Giorgi, MD, PhD,5 Jae Young Joung, MD, PhD,6 Peter C. Fong, MD,7 Robert J. Jones, PhD, MBChB,8 Stefanie Zschäbitz, MD,9 Jan Oldenburg, MD, PhD,10 Neal D…

Thumbnail for JL1131ES: Tumor Treating Fields therapy for glioblastoma: identifying needs and satisfaction of new and long-term users

JL1131ES: Tumor Treating Fields therapy for glioblastoma: identifying needs and satisfaction of new and long-term users

Eleni T…

Thumbnail for JL1125ES: Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

JL1125ES: Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

Martin Reck, MD, PhD1, Ana Laura Ortega Granados, MD2, Filippo de Marinis, MD3, Oren Meyers, PhD4, Susan Boklage, MS, MPH4, Qin Shen, PhD4, Lillian Cho, PharmD4